Drugs Containing Excipient (Inactive Ingredient) ETHYLHEXYLGLYCERIN

Generic drugs containing ETHYLHEXYLGLYCERIN excipient

Company	Ingredient	NDC	Excipient
Guangdong Quadrant Ecological Technology Co Ltd	hair growth foam (men)	76986-008	ETHYLHEXYLGLYCERIN
Guangdong Quadrant Ecological Technology Co Ltd	hair growth foam (women)	76986-009	ETHYLHEXYLGLYCERIN
GUANGZHOU NODA PHARMACEUTICAL TECHNOLOGY INCORPORATED CO LTD	elevate 5% minoxidil foam	78098-301	ETHYLHEXYLGLYCERIN
GUANGZHOU NODA PHARMACEUTICAL TECHNOLOGY INCORPORATED CO LTD	elevate 5% minoxidil hair liquid	78098-303	ETHYLHEXYLGLYCERIN
Xiamen Panmai Technology Co Ltd	hair regrowth ireatment	83788-301	ETHYLHEXYLGLYCERIN

Ethylhexylglycerin Market Dynamics, Pharmaceutical Excipient Demand, and Financial Trajectory

Last updated: August 6, 2026

Ethylhexylglycerin is a multifunctional cosmetic and topical-formulation ingredient with demand driven by preservative-boosting, deodorant, skin-conditioning, and antimicrobial-support applications. Its commercial market is fragmented, with no reliable public revenue figure for the molecule alone. Growth is tied more closely to premium personal care, preservative-free positioning, and topical pharmaceutical formulation activity than to traditional high-volume oral drug excipient demand.

What is ethylhexylglycerin and how is it used?

Ethylhexylglycerin, also known as glyceryl mono-2-ethylhexyl ether, has CAS No. 70445-33-9 and the INCI name Ethylhexylglycerin. It is a glycerol ether derived from glycerin and 2-ethylhexanol.

Its principal functions are:

• Preservative booster
• Skin-conditioning agent
• Deodorant ingredient
• Antimicrobial-support ingredient
• Emulsion and formulation aid in topical products

Ethylhexylglycerin is usually not the sole preservative in a formulation. It is commonly combined with phenoxyethanol, organic acids, glycols, caprylyl glycol, or other preservation systems. The combination can improve microbial control while reducing the concentration of conventional preservatives.

The ingredient is most established in:

• Skin-care products
• Deodorants and antiperspirants
• Hair-care products
• Makeup and color cosmetics
• Wet wipes
• Sunscreens
• Dermatological creams and lotions
• Topical pharmaceutical products
• Some medical and hygiene formulations

The molecule is commercially distinct from ethylhexyl palmitate, ethylhexyl methoxycinnamate, and other 2-ethylhexyl derivatives used in personal care.

How large is the ethylhexylglycerin market?

No audited public market series isolates ethylhexylglycerin revenue from broader preservative, cosmetic ingredient, or multifunctional additive markets. Commercial market reports often combine the ingredient with related glycerol ethers or preservative blends, producing estimates that are not directly comparable.

The market is best evaluated through demand indicators rather than a single headline market size.

Market indicator	Direction	Commercial effect
Premium skin care	Positive	Increases demand for multifunctional ingredients
Deodorant reformulation	Positive	Supports use as a deodorant and odor-control aid
“Paraben-free” and mild-preservative positioning	Positive	Supports preservative-booster demand
Conventional oral pharmaceutical excipient demand	Limited	Ethylhexylglycerin is not a major high-volume oral excipient
Topical pharmaceutical products	Moderate positive	Supports demand in creams, gels, lotions, and sprays
Regulatory scrutiny of preservatives	Mixed	Encourages substitution but increases documentation costs
Raw-material volatility	Negative	Pressures margins and contract pricing
Supplier consolidation	Mixed	Improves technical support but can increase dependence on qualified sources

The commercial market is therefore a specialty-ingredient market rather than a bulk pharmaceutical excipient market. Pricing is influenced by purity, microbiological specifications, regional registration, packaging, supply continuity, and whether the material is sold as a neat ingredient or in a proprietary preservative blend.

What is the financial trajectory for ethylhexylglycerin?

The financial trajectory is likely to remain positive but moderate, with growth concentrated in higher-value applications rather than large-volume pharmaceutical manufacturing.

Revenue drivers

The strongest revenue drivers are:

1. Growth in facial skin care and dermocosmetics.
2. Demand for mild-preservative systems.
3. Expansion of deodorant and odor-control products.
4. Use in water-based formulations that require preservation support.
5. Premiumization of cosmetic and dermatological products.
6. Outsourced formulation and contract manufacturing.
7. Increased use of multifunctional ingredients to reduce formulation complexity.

Ethylhexylglycerin can create economic value by replacing part of a conventional preservative system, reducing the number of separate ingredients, or supporting a product claim based on mildness and formulation acceptability.

Margin profile

The ingredient is more likely to generate specialty-chemical margins than commodity glycerin margins. Suppliers compete on:

• Consistent purity
• Odor and color profile
• Batch-to-batch performance
• Low residual impurities
• Global regulatory documentation
• Compatibility with emulsions and surfactant systems
• Technical support
• Supply reliability

Price competition is stronger when customers purchase neat ethylhexylglycerin for standard cosmetic applications. Pricing power improves when a supplier sells a validated blend, supports formulation work, or has a customer-specific qualification.

Financial risks

The main risks are raw-material costs, especially glycerin and 2-ethylhexanol economics; customer reformulation; regional regulatory changes; and substitution by caprylyl glycol, glyceryl caprylate, organic acids, multifunctional glycols, or established preservative blends.

Public companies generally report ethylhexylglycerin within broader specialty-ingredient or care-chemical segments. They do not normally disclose separate sales, volume, or operating profit for this molecule. As a result, company-level revenue exposure cannot be calculated from annual reports without internal product-level data.

Which companies manufacture or supply ethylhexylglycerin?

The supply base includes specialty cosmetic-ingredient manufacturers, preservative-system companies, distributors, and regional chemical producers. Major commercial competition is based on formulation support and regulatory coverage rather than on a single protected manufacturing technology.

Known market participants and product associations include:

Company	Relevant commercial position
Symrise	Supplies ethylhexylglycerin-based preservation and antimicrobial systems, including Sensiva-branded products
Schülke	Supplies preservation systems and antimicrobial technologies used in personal care and topical formulations
Ashland	Participates in cosmetic and pharmaceutical formulation ingredients, although product-level ethylhexylglycerin exposure is not usually disclosed
Thor Personal Care	Supplies preservative systems and multifunctional antimicrobial ingredients
Connect Chemicals	Supplies specialty cosmetic ingredients, including preservative-related materials
Regional Asian manufacturers	Compete on bulk supply, export availability, and price
Distributors	Provide local inventory, documentation, and regulatory support

Symrise identifies cosmetic ingredients, preservation, and care solutions within its broader Consumer segment, but its public reporting does not separately quantify ethylhexylglycerin sales.[1] Supplier portfolios should be reviewed at the product level because some brands contain ethylhexylglycerin in combination with other active or functional ingredients.

What is the FDA regulatory status of ethylhexylglycerin?

Ethylhexylglycerin is primarily regulated according to the use category and jurisdiction.

In the United States, cosmetic ingredients generally do not require premarket approval, except for color additives. The manufacturer remains responsible for product safety and labeling under the Federal Food, Drug, and Cosmetic Act.[2] Ethylhexylglycerin is not an FDA-approved active pharmaceutical ingredient.

For pharmaceutical products, its status depends on the dosage form, route of administration, concentration, and the regulatory basis for the finished product. A topical drug manufacturer must support the ingredient as an inactive component through formulation-specific safety and regulatory documentation.

The FDA Inactive Ingredient Database is relevant when assessing prior use in approved drug products. Database presence does not automatically establish approval for every route, concentration, or dosage form.[3]

Is ethylhexylglycerin in the Orange Book?

Ethylhexylglycerin does not have an Orange Book patent or exclusivity position because it is an excipient, not an approved active drug substance. The Orange Book lists approved drug products, therapeutic equivalence information, and certain patents and exclusivities associated with those products. It does not create a standalone patent estate for excipients.[4]

A finished topical drug containing ethylhexylglycerin could have patents covering its active ingredient, formulation, delivery system, or method of use. Those rights would belong to the drug product and would not establish proprietary control over ethylhexylglycerin itself.

What are the European regulatory requirements?

Ethylhexylglycerin is listed in the European Commission CosIng database under the cosmetic ingredient name Ethylhexylglycerin.[5] Its common cosmetic functions include skin conditioning and deodorant use.

Cosmetic use in the European Union remains subject to:

• Regulation (EC) No. 1223/2009
• Product safety assessment
• Product Information File requirements
• Good manufacturing practice
• Correct ingredient labeling
• Responsible-person obligations
• Restrictions applicable to the finished formulation

CosIng database inclusion is not equivalent to a general safety authorization for every concentration or use. The safety assessment must address the complete product, exposure, impurities, and combination with other ingredients.

For pharmaceutical products, European excipient status is separate from cosmetic status. A supplier normally must provide quality specifications, toxicology information, residual solvent data, elemental impurity information, microbiological controls, and manufacturing documentation suitable for the intended medicinal product.

What formulations are protected by ethylhexylglycerin?

Ethylhexylglycerin can appear in several formulation categories, but the ingredient itself generally does not provide exclusivity.

Potentially protectable formulation elements include:

• A specific preservative combination
• Defined concentration ranges
• A topical cream, gel, lotion, foam, spray, or wipe
• Improved antimicrobial performance
• Reduced irritation or sensitization
• Enhanced stability under defined pH conditions
• Compatibility with a particular active pharmaceutical ingredient
• A delivery system, such as a nanoemulsion or polymeric gel
• A manufacturing sequence that improves dispersion or uniformity
• A method of treating a dermatological condition

Patents in this area would normally be owned by the finished-product developer, not by the excipient manufacturer. Patent strength depends on claim breadth, experimental support, prior art, prosecution history, and the ability to prove infringement from the finished product.

How strong is the patent estate for ethylhexylglycerin?

The core patent estate appears weak as a source of molecule-level exclusivity because ethylhexylglycerin is an established chemical ingredient with broad prior commercial use.

The commercially relevant intellectual-property layers are more likely to be:

1. Proprietary preservative blends.
2. Formulation-specific composition claims.
3. Manufacturing and purification processes.
4. Supplier trademarks and product names.
5. Customer-specific technical data packages.
6. Trade secrets concerning production, impurity control, and blending.

A supplier may protect a branded system containing ethylhexylglycerin even where the underlying molecule is available from competing manufacturers. Trademark protection and technical qualification can create commercial switching costs without blocking generic chemical production.

No meaningful Orange Book or Paragraph IV framework applies to ethylhexylglycerin as a standalone excipient. Paragraph IV litigation concerns patents listed for approved drug products, not ordinary cosmetic ingredients or unlisted excipients.[4]

Are there biosimilar, generic-entry, or litigation risks?

Biosimilar risk is not relevant because ethylhexylglycerin is a small chemical ingredient, not a biologic.

Generic-entry risk is relevant only at the finished-product level. A generic topical drug could use ethylhexylglycerin if its formulation, regulatory filing, and patent position permit that use. The excipient itself is generally available from multiple sources, so supply qualification rather than molecule-level exclusivity is the principal barrier.

Litigation risks may involve:

• Formulation patents
• Method-of-treatment claims
• Infringement disputes over preservative systems
• Trade-secret claims involving manufacturing
• Product-quality disputes
• Regulatory claims concerning cosmetic or drug labeling
• Contract disputes over specifications or supply continuity

Publicly visible litigation focused specifically on ethylhexylglycerin as the asserted invention is limited. The more important legal exposure lies in finished topical products and branded preservation technologies.

How does ethylhexylglycerin compare with competing preservatives?

Ingredient or system	Primary role	Competitive position
Ethylhexylglycerin	Preservative booster, deodorant, skin conditioning	Strong in premium cosmetic and topical systems
Phenoxyethanol	Broad-use preservative	Higher-volume and widely recognized
Caprylyl glycol	Humectant and antimicrobial booster	Direct multifunctional substitute
Glyceryl caprylate	Antimicrobial and emollient	Useful in natural-positioned systems
Sorbic acid and benzoic acid	Organic-acid preservation	Strong where low-pH systems are acceptable
Benzyl alcohol	Preservative and fragrance component	Established but formulation and labeling constraints apply
1,2-Hexanediol	Humectant and preservative booster	Competes in mild-preservative formulations
Parabens	Established preservatives	Effective but commercially weaker in “paraben-free” segments

Ethylhexylglycerin’s advantage is multifunctionality. Its limitation is that it often requires combination with another preservative or antimicrobial system to achieve broad protection.

What geographic markets are most important?

Europe remains important because of the region’s advanced cosmetic-ingredient industry, high demand for mild and multifunctional formulations, and extensive supplier documentation requirements.

North America is attractive because of strong skin-care, deodorant, dermatology, and contract-manufacturing markets. Regulatory classification differs between cosmetics and drugs, which increases the value of formulation and compliance support.

Asia-Pacific is likely to provide the strongest volume growth potential because of expanding personal-care manufacturing, rising middle-class consumption, and large regional production bases. China, South Korea, Japan, and India are important supply and demand centers, although registration, import, and documentation requirements differ by country.

Geographic competitiveness depends on:

• Local inventory
• Export controls and customs requirements
• Regional cosmetic inventories
• Pharmaceutical-grade documentation
• Supplier audit history
• Availability of alternate sources
• Ability to support local-language regulatory filings

What manufacturing and IP barriers affect supply?

The chemical synthesis route is not generally regarded as an insurmountable manufacturing barrier. Commercial barriers arise from process control and qualification.

Important manufacturing parameters include:

• Reaction conversion
• Residual starting materials
• Color and odor
• Water content
• Residual solvents
• Heavy metals and elemental impurities
• Microbial quality
• Batch consistency
• Packaging compatibility
• Long-term stability

Pharmaceutical customers may require supplier audits, change-control commitments, validated analytical methods, stability data, and multi-year supply agreements. These requirements can exclude low-cost suppliers even when the chemical product is nominally equivalent.

The strongest defensible positions are often trade secrets, process know-how, customer qualification, and regulatory files rather than composition-of-matter patents.

What is the outlook for ethylhexylglycerin through the next market cycle?

The base-case outlook is steady expansion, led by cosmetics and topical formulations. Growth should be strongest where formulators seek multifunctional ingredients and reduced reliance on conventional preservative systems.

The principal upside scenario involves wider adoption in dermatological products, deodorants, wipes, and preservation systems marketed around mildness. The downside scenario involves substitution by lower-cost glycols, organic acids, or preservative blends and increased scrutiny of sensitization or environmental profiles.

Ethylhexylglycerin is unlikely to become a major standalone oral pharmaceutical excipient. Its stronger commercial position is in topical, dermocosmetic, and personal-care formulations where preservation support and sensory performance carry meaningful value.

Key Takeaways

• Ethylhexylglycerin is a specialty multifunctional ingredient, not a major bulk oral pharmaceutical excipient.
• Its main functions are preservative boosting, deodorant support, and skin conditioning.
• No reliable public source reports standalone global revenue for the molecule.
• Financial growth is most closely linked to skin care, deodorants, dermocosmetics, and topical formulations.
• The FDA does not approve ethylhexylglycerin as an active drug ingredient.
• It has no standalone Orange Book patent, exclusivity, or Paragraph IV position.
• The commercial IP landscape centers on blends, formulations, manufacturing know-how, trademarks, and customer qualification.
• Europe, North America, and Asia-Pacific are the key geographic markets.
• The strongest competitive advantage is regulatory and technical support combined with reliable supply.
• Long-term growth is likely to be moderate, with higher margins in validated preservative systems than in commodity neat-ingredient sales.

FAQs

Is ethylhexylglycerin a pharmaceutical preservative?

Ethylhexylglycerin can support preservation in topical pharmaceutical formulations, but it is not generally used as a standalone broad-spectrum preservative. Its suitability depends on the dosage form, concentration, pH, microbial challenge data, and regulatory justification.

Is ethylhexylglycerin natural or synthetic?

Commercial ethylhexylglycerin is produced through chemical synthesis using glycerin-derived and 2-ethylhexyl-derived raw materials. “Natural” positioning depends on the supplier’s production route, certification, and the standard applied by the finished-product marketer.

Can ethylhexylglycerin replace phenoxyethanol?

Usually not on a one-for-one basis. Ethylhexylglycerin is commonly used with phenoxyethanol or another preservative because it improves antimicrobial performance but may not provide complete broad-spectrum preservation alone.

Does ethylhexylglycerin have a pharmacopeial monograph?

It is not generally treated as a major compendial excipient with the market prominence of glycerin, propylene glycol, or polyethylene glycol. Pharmaceutical acceptability must be assessed through the applicable jurisdiction, product route, supplier quality data, and finished-product filing.

Who owns the main ethylhexylglycerin patents?

No single company appears to control a broad molecule-level patent monopoly for commercially used ethylhexylglycerin. Relevant rights are more likely to cover proprietary blends, formulations, production processes, trademarks, and application-specific technology.

References

1. Symrise AG. (2024). Annual report 2023. Symrise AG.

2. U.S. Food and Drug Administration. (2023). Cosmetics and the law. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services.

5. European Commission. (2024). CosIng: Cosmetic ingredients and substances database, Ethylhexylglycerin. European Commission.